-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Evommune, Raises Price Target to $65

Benzinga·02/10/2026 18:05:23
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Evommune (NYSE:EVMN) with a Buy and raises the price target from $35 to $65.